Cargando…
Novel therapeutic agents for cutaneous T-Cell lymphoma
Mycosis fungoides (MF) and Sezary Syndrome (SS) represent the most common subtypes of primary Cutaneous T-cell lymphoma (CTCL). Patients with advanced MF and SS have a poor prognosis leading to an interest in the development of new therapies with targeted mechanisms of action and acceptable safety p...
Autores principales: | Jain, Salvia, Zain, Jasmine, O’Connor, Owen |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2012
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3418166/ https://www.ncbi.nlm.nih.gov/pubmed/22594538 http://dx.doi.org/10.1186/1756-8722-5-24 |
Ejemplares similares
-
Romidepsin in the treatment of cutaneous T-cell lymphoma
por: Jain, Salvia, et al.
Publicado: (2011) -
Emerging role of carfilzomib in treatment of relapsed and refractory lymphoid neoplasms and multiple myeloma
por: Jain, Salvia, et al.
Publicado: (2011) -
Targeting histone deacetyalses in the treatment of B- and T-cell malignancies
por: Zain, Jasmine, et al.
Publicado: (2010) -
Epigenetics of cutaneous T-cell lymphoma: biomarkers and therapeutic potentials
por: Lai, Pan, et al.
Publicado: (2021) -
Real-world experience of combined treatment with azacitidine and romidepsin in patients with peripheral T-cell lymphoma
por: Kalac, Matko, et al.
Publicado: (2023)